Steve Balt, MD
Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center
Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb.Talia Puzantian, PharmD, BCPP
Clinical psychopharmacology consultant in private practice, Los Angeles, CA.
Dr. Puzantian has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
Since 2011, 3 new antidepressants have been approved by the FDA, and another (ketamine) has been generating buzz as a potential off-label medication for depression. In this article, we’ll take a step back and review the data on vilazodone (Viibryd), levomilnacipran (Fetzima), vortioxetine (Brintellix), and ketamine.